$ACB

Tilray (TLRY) rose 6% to $4.75, Canopy Growth (CGC) 3% to $1.02, and Aurora Cannabis (ACB) 4% to $3.80, driven by Treasury buybacks lowering yields. Tilray is still down 47% YTD, despite diversification into non-cannabis segments. The cannabis sector's performance varies, with ETFs like MJ and MSOS showing mixed results.

Aurora Cannabis (ACB) acquired Internode Pharma and HAP Pharma to expand its UK medical cannabis market presence. The move aims to boost distribution, market share, and product supply. According to CEO Miguel Martin, the deal aligns with Aurora's strategy to grow in the international medical cannabis market.

Aurora Cannabis (TSX: ACB, NASDAQ: ACB) has urged shareholders to take no action regarding Curaleaf's (TSX: CURA, OTCQX: CURLF) unsolicited takeover bid of $4.00 per share, consisting of 0.3463 Curaleaf shares plus $0.75 in cash. Aurora's CEO, Miguel Martin, stated that Curaleaf's offer is designed to pressure shareholders into a short-term decision. Aurora has engaged with Curaleaf since June 2026 and plans to provide a comprehensive response to shareholders in due course.

Curaleaf (CURLF) offered to buy Aurora Cannabis (ACB) for $272M, a 45% premium. The deal aims to create a company with $1.5B revenue and $350M EBITDA. Canopy Growth (CGC) may also attract takeover interest due to its global medical cannabis assets and strategic U.S. market exposure, but its complex structure and integration risks are noted.

Curaleaf has made a public hostile bid for Aurora, offering $4 per share, a 45% premium on Aurora's 30-day average. Curaleaf aims to create a $3B combined company with cost synergies and access to EU medical cannabis markets. Aurora's board is reviewing the deal. Shares of both companies moved on the news.

Curaleaf Holdings launched a takeover bid for Aurora Cannabis valuing it at about US$260 million, a week after its initial proposal, according to Curaleaf and Reuters. Aurora shareholders would receive 0.3463 Curaleaf shares and $0.75 cash per share, about $4 total, with a cap tied to Curaleaf’s stock. The offer runs until Dec. 1 pending approvals and majority support.

Curaleaf Holdings launched a takeover bid for Aurora Cannabis valuing it at about US$260 million. Aurora shareholders would receive 0.3463 Curaleaf shares plus $0.75 cash per share, totaling $4 per share, with a cap at $5 if Curaleaf stock rises. The offer runs until Dec. 1, pending approvals and majority support. Aurora shares rose 3% early.

Curaleaf Holdings (TSE:CURA) launched a hostile takeover bid for Aurora Cannabis, offering US$4.00 per share (45% premium) via a mix of shares and cash. The bid, open until December 1, 2026, aims to address Aurora's regulatory and financial challenges, offering immediate value and equity participation. Curaleaf highlights its stronger financial position and global scale. Analysts rate CURA as Buy (C$21.00 target) and Neutral (Spark's AI).

Curaleaf has offered to acquire Aurora Cannabis at $4.00 per share, a 45% premium. The bid includes 0.3463 Curaleaf shares and $0.75 cash per Aurora share, based on Curaleaf's stock price of $9.39 on August 10, 2026. The offer is open until December 1, 2026, and is not subject to financing or due diligence conditions. Curaleaf aims to achieve cost synergies and access to the U.S. market. Aurora's board declined prior engagement but has formed a Special Committee.

Curaleaf (TSX: CURA) launched a US$4.00 per share takeover bid for Aurora Cannabis (TSX: ACB), offering 0.3463 shares plus US$0.75 cash per share. The bid, a 45% premium over Aurora's 30-day average, requires over 50% shareholder approval and expires December 1. Curaleaf claims Aurora ignored negotiations, while Aurora disputes this and is evaluating the offer.